Background
When two licensed drugs are mixed together in a syringe, the result is regarded as a new, unlicensed product according to the Medicines Act and therefore the MHRA, whose purpose is to regulate all issues regarding manufacture and distribution of drugs.
Whilst this does not appear to have any direct consequences on the process itself, it limits the personnel who are legallly able to prescribe such mixtures to medical prescribers and also disallows any such mixing within a Patient Group Direction. However, if a clinical management plan (CMP) is drawn up, an independent non-medical prescriber can act as a supplemetary prescriber and prescribe an unlicensed product.
Templates
The following template has been provided by Jane Nicholls, Jane Nicholls, Associate Director of Clinical Pharmacy, East & South East England Specialist Pharmacy Services NHS and London Pharmacist Prescribing Project Lead. It has been modified from a heart failure template but the essential elements are the same.
The second example is one with more specific details included and may also be used as an example.
Your attention is drawn to the guidance that must be used in conjunction with these CMPs
general template
